<?xml version='1.0' encoding='utf-8'?>
<document id="26692748"><sentence text="Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5'-diphospho-glucuronosyltransferase isoforms."><entity charOffset="11-22" id="DDI-PubMed.26692748.s1.e0" text="mitragynine" /><entity charOffset="27-47" id="DDI-PubMed.26692748.s1.e1" text="7-hydroxymitragynine" /><entity charOffset="53-62" id="DDI-PubMed.26692748.s1.e2" text="alkaloids" /><entity charOffset="95-116" id="DDI-PubMed.26692748.s1.e3" text="4-methylumbelliferone" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e0" e2="DDI-PubMed.26692748.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e0" e2="DDI-PubMed.26692748.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e0" e2="DDI-PubMed.26692748.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e0" e2="DDI-PubMed.26692748.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e1" e2="DDI-PubMed.26692748.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e1" e2="DDI-PubMed.26692748.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e1" e2="DDI-PubMed.26692748.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e2" e2="DDI-PubMed.26692748.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s1.e2" e2="DDI-PubMed.26692748.s1.e3" /></sentence><sentence text="Glucuronidation catalyzed by uridine 5'- diphospho-glucuronosyltransferase (UGT) is a major phase II drug metabolism reaction which facilitates drug elimination" /><sentence text=" Inhibition of UGT activity can cause drug-drug interaction" /><sentence text=" Therefore, it is important to determine the inhibitory potentials of drugs on glucuronidation" /><sentence text="" /><sentence text="The objective was to evaluate the inhibitory potentials of mitragynine, 7-hydroxymitragynine, ketamine and buprenorphine, respectively on 4-methylumbelliferone (4-MU) glucuronidation in rat liver microsomes, human liver microsomes and recombinant human UGT1A1 and UGT2B7 isoforms"><entity charOffset="59-70" id="DDI-PubMed.26692748.s6.e0" text="mitragynine" /><entity charOffset="72-92" id="DDI-PubMed.26692748.s6.e1" text="7-hydroxymitragynine" /><entity charOffset="94-102" id="DDI-PubMed.26692748.s6.e2" text="ketamine" /><entity charOffset="107-120" id="DDI-PubMed.26692748.s6.e3" text="buprenorphine" /><entity charOffset="138-159" id="DDI-PubMed.26692748.s6.e4" text="4-methylumbelliferone" /><entity charOffset="161-165" id="DDI-PubMed.26692748.s6.e5" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e0" e2="DDI-PubMed.26692748.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e1" e2="DDI-PubMed.26692748.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e1" e2="DDI-PubMed.26692748.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e1" e2="DDI-PubMed.26692748.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e1" e2="DDI-PubMed.26692748.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e1" e2="DDI-PubMed.26692748.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e2" e2="DDI-PubMed.26692748.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e2" e2="DDI-PubMed.26692748.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e2" e2="DDI-PubMed.26692748.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e2" e2="DDI-PubMed.26692748.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e3" e2="DDI-PubMed.26692748.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e3" e2="DDI-PubMed.26692748.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e3" e2="DDI-PubMed.26692748.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e4" e2="DDI-PubMed.26692748.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26692748.s6.e4" e2="DDI-PubMed.26692748.s6.e5" /></sentence><sentence text="" /><sentence text="The effects of the above four compounds on the formation of 4-MU glucuronide from 4-MU by rat liver microsomes, human liver microsomes, recombinant human UGT1A1 and UGT2B7 isoforms were determined using high-performance liquid chromatography with ultraviolet detection"><entity charOffset="60-76" id="DDI-PubMed.26692748.s8.e0" text="4-MU glucuronide" /><entity charOffset="82-86" id="DDI-PubMed.26692748.s8.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s8.e0" e2="DDI-PubMed.26692748.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s8.e0" e2="DDI-PubMed.26692748.s8.e1" /></sentence><sentence text="" /><sentence text="For rat liver microsomes, ketamine strongly inhibited 4-MU glucuronidation with an IC50 value of 6"><entity charOffset="26-34" id="DDI-PubMed.26692748.s10.e0" text="ketamine" /><entity charOffset="54-61" id="DDI-PubMed.26692748.s10.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s10.e0" e2="DDI-PubMed.26692748.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s10.e0" e2="DDI-PubMed.26692748.s10.e1" /></sentence><sentence text="21 ± 1" /><sentence text="51 μM followed by buprenorphine with an IC50 value of 73"><entity charOffset="18-31" id="DDI-PubMed.26692748.s12.e0" text="buprenorphine" /></sentence><sentence text="22 ± 1" /><sentence text="63 μM" /><sentence text=" For human liver microsomes, buprenorphine strongly inhibited 4-MU glucuronidation with an IC50 value of 6"><entity charOffset="29-42" id="DDI-PubMed.26692748.s15.e0" text="buprenorphine" /><entity charOffset="62-74" id="DDI-PubMed.26692748.s15.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s15.e0" e2="DDI-PubMed.26692748.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s15.e0" e2="DDI-PubMed.26692748.s15.e1" /></sentence><sentence text="32 ± 1" /><sentence text="39 μM" /><sentence text=" For human UGT1A1 isoform, 7-hydroxymitragynine strongly inhibited 4-MU glucuronidation with an IC50 value of 7"><entity charOffset="27-47" id="DDI-PubMed.26692748.s18.e0" text="7-hydroxymitragynine" /><entity charOffset="67-86" id="DDI-PubMed.26692748.s18.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s18.e0" e2="DDI-PubMed.26692748.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s18.e0" e2="DDI-PubMed.26692748.s18.e1" /></sentence><sentence text="13 ± 1" /><sentence text="16 μM" /><sentence text=" For human UGT2B7 isoform, buprenorphine strongly inhibited 4-MU glucuronidation followed by 7-hydroxymitragynine and ketamine with respective IC50 values of 5"><entity charOffset="27-40" id="DDI-PubMed.26692748.s21.e0" text="buprenorphine" /><entity charOffset="93-113" id="DDI-PubMed.26692748.s21.e1" text="7-hydroxymitragynine" /><entity charOffset="118-126" id="DDI-PubMed.26692748.s21.e2" text="ketamine" /><entity charOffset="60-67" id="DDI-PubMed.26692748.s21.e3" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e0" e2="DDI-PubMed.26692748.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e0" e2="DDI-PubMed.26692748.s21.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e0" e2="DDI-PubMed.26692748.s21.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e0" e2="DDI-PubMed.26692748.s21.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e3" e2="DDI-PubMed.26692748.s21.e3" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e3" e2="DDI-PubMed.26692748.s21.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e3" e2="DDI-PubMed.26692748.s21.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e1" e2="DDI-PubMed.26692748.s21.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s21.e1" e2="DDI-PubMed.26692748.s21.e2" /></sentence><sentence text="14 ± 1" /><sentence text="30, 26" /><sentence text="44 ± 1" /><sentence text="31, and 27" /><sentence text="28 ± 1" /><sentence text="18 μM" /><sentence text="" /><sentence text="These data indicate the possibility of drug-drug interaction if 7-hydroxymitragynine, ketamine, and buprenorphine are co-administered with drugs that are UGT2B7 substrates since these three compounds showed significant inhibition on UGT2B7 activity"><entity charOffset="64-84" id="DDI-PubMed.26692748.s29.e0" text="7-hydroxymitragynine" /><entity charOffset="86-94" id="DDI-PubMed.26692748.s29.e1" text="ketamine" /><entity charOffset="100-113" id="DDI-PubMed.26692748.s29.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.26692748.s29.e0" e2="DDI-PubMed.26692748.s29.e0" /><pair ddi="false" e1="DDI-PubMed.26692748.s29.e0" e2="DDI-PubMed.26692748.s29.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s29.e0" e2="DDI-PubMed.26692748.s29.e2" /><pair ddi="false" e1="DDI-PubMed.26692748.s29.e1" e2="DDI-PubMed.26692748.s29.e1" /><pair ddi="false" e1="DDI-PubMed.26692748.s29.e1" e2="DDI-PubMed.26692748.s29.e2" /></sentence><sentence text=" In addition, if 7-hydroxymitragynine is to be taken with other drugs that are highly metabolized by UGT1A1, there is a possibility of drug-drug interaction to occur"><entity charOffset="17-37" id="DDI-PubMed.26692748.s30.e0" text="7-hydroxymitragynine" /></sentence><sentence text="" /></document>